Recruiting REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis NCT06315010 Conditions Brain Diseases, Brain Metastases, Brain Neoplasms, +16 more Locations Medizinische Universität Graz — Graz, Austria Medical University of Vienna — Vienna, Austria Ludwig-Maximilians-University Munich — München, Germany Hospital de Vinalopó — Elche, Alicante, Spain View all 16 locations View more locations Show fewer locations Loading locations... View Trial Details
Not Yet Recruiting Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC NCT06694129 Conditions Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +11 more Locations Not specified View Trial Details
Completed Study of Crizotinib for ROS1 and MET Activated Lung Cancer NCT04084717 Conditions Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +12 more Locations Princess Margaret Cancer Centre — Toronto, Ontario, Canada View Trial Details
Active, Not Recruiting Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer NCT02321501 Conditions ALK Positive, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, +8 more Locations M D Anderson Cancer Center — Houston, Texas, United States View Trial Details
